Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Investing

Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales

admin by admin
July 14, 2025
in Investing
0
Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive Officer Thibaut Mongon has stepped down.

Kenvue shares were up by more than 6% during pre-market on the back of the announcement.

Board director Kirk Perry has been named interim CEO while the company undergoes a strategic review aimed at simplifying its operations and strengthening performance after a challenging quarter.

The change at the top comes amid ongoing struggles for the consumer health company, which has been contending with softer consumer demand, inventory reductions by retailers, and pressures from tariffs in key international markets.

Mongon’s departure follows the appointment of a new chief financial officer in May, when Amit Banati replaced Paul Ruh.

In a statement, Kenvue Chair Larry Merlo said the board has full confidence in the interim leadership and the direction the company is taking.

“We are confident that the steps we are taking put Kenvue on the right path to deliver both near- and long-term value creation for shareholders,” said Chair Larry Merlo.

Second-quarter results point to continuing slowdown

Preliminary second-quarter results released by the company on Monday underscore the challenges it faces.

Kenvue said it expects sales to decline 4% for the quarter ended June 29, with adjusted earnings per share forecast between 28 cents and 29 cents.

The company plans to issue its full second-quarter report and revise its full-year guidance on August 7.

While the expected earnings per share are broadly in line with analyst expectations compiled by LSEG, the sales decline reflects broader macroeconomic pressures affecting the consumer health sector.

In June, Mongon said the company was adjusting its pricing strategy and grappling with destocking by retailers, particularly in China.

The headwinds are expected to weigh on results into the second half of the year.

Company weighs portfolio changes and brand divestitures

As part of its broader strategic review, Kenvue is evaluating options to simplify its product portfolio.

People familiar with the matter told Reuters in June that the company is exploring the sale of several smaller skin health and beauty brands, including Clean & Clear, Maui Moisture, Neostrata, Bebe, and Dr.Ci:Labo.

Kenvue intends to retain more prominent brands such as Neutrogena and Aveeno, which remain central to its consumer health strategy.

The board has formed a dedicated committee to oversee the review process and is being advised by Centerview Partners and McKinsey & Company.

Merlo said the company is considering a wide range of potential alternatives, not only in terms of product lines but also operational structure.

The strategic pivot reflects Kenvue’s effort to reestablish growth momentum following a slow start to the year.

While the company has maintained a stable of well-known consumer products, it now faces pressure to trim underperforming segments and refine its focus in an increasingly competitive environment.

The results of the review, as well as guidance for 2025, are expected to become clearer when the company delivers its full quarterly earnings in early August.

The post Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales appeared first on Invezz

Previous Post

US markets open in red amid new tariff concerns, earnings season to start this week

Next Post

Rivian faces downgrades and demand concerns amid EV incentive cuts

admin

admin

Next Post
Rivian faces downgrades and demand concerns amid EV incentive cuts

Rivian faces downgrades and demand concerns amid EV incentive cuts

Trending News

Lyft shares continue slide after Q4 earnings: here’s why the stock is down 14%

Lyft shares continue slide after Q4 earnings: here’s why the stock is down 14%

February 12, 2025
Long BAX: Baxter International Surges Post-Earnings, Institutional Investments Signal Continued Growth

Long BAX: Baxter International Surges Post-Earnings, Institutional Investments Signal Continued Growth

February 24, 2025
Rusal’s new claims against Nornickel’s Potanin: what’s at stake for shareholders?

Rusal’s new claims against Nornickel’s Potanin: what’s at stake for shareholders?

November 2, 2024
Subscribe to Insightful Word


    Recent News

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    August 27, 2025
    Webull stock price is in a deep slumber: will it wake up after earnings?

    Webull stock price is in a deep slumber: will it wake up after earnings?

    August 27, 2025
    Wall Street braces as Nvidia earnings test AI boom and China risks

    Wall Street braces as Nvidia earnings test AI boom and China risks

    August 27, 2025
    US stocks open flat ahead of Nvidia earnings: Dow up 25 pts, Nasdaq slips 0.1%

    US stocks open flat ahead of Nvidia earnings: Dow up 25 pts, Nasdaq slips 0.1%

    August 27, 2025

    Recent News

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates

    August 27, 2025
    Webull stock price is in a deep slumber: will it wake up after earnings?

    Webull stock price is in a deep slumber: will it wake up after earnings?

    August 27, 2025

    Latest News

    • Hyperliquid (HYPE) hits $50 ATH as institutional adoption accelerates
    • Webull stock price is in a deep slumber: will it wake up after earnings?
    • Wall Street braces as Nvidia earnings test AI boom and China risks

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.